atrial or ventricular contractions (PACs/PVCs), bigeminy/ trigeminy, sinus dysrhythmias, or occasionally even nonsustained ventricular tachycardia. 1 , 2 , 7 In a patient with known cardiac dysrhythmias at baseline, the additional stress of acceleration might induce signifi cant dysrhythmias that place the patient at risk for adverse outcomes, such as incapacitation, cardiac dysfunction, and death. 6 Potential concerns for the use of CIDs in spacefl ight include acceleration exposure causing lead displacement and loss of eff ective pacing, device malfunction, and increased arrhythmogenesis that exceeds the pacing capabilities of the CID. Individuals requiring the use of an implanted automated defi brillator have, by defi nition, serious medical conditions that pose significant risk during spacefl ight. In addition, defi brillation devices pose other risks, including potential misinterpretation of altered rhythms (such as the presence of increased numbers of PACs and PVCs as would be expected during acceleration) with administration of unnecessary shock, inadvertent transfer of electricity during defi brillation to the vehicle systems or other occupants, and the incapacitation of an individual following defi brillation.
Th e prevalence of CIDs and the lack of understanding of the risks involved during spacefl ight for device-dependent individuals have led to a need to address this knowledge gap. For this reason, we examined the responses of two volunteer subjects with CIDs to G forces in a centrifuge to evaluate how similar commercial SFPs might tolerate the acceleration forces involved in the launch and reentry profiles of commercial spacefl ight. Th eir participation was part of a larger trial that has been previously published.
1

CASE REPORTS
Two subjects, 75-and 79-yr-old men with histories of atrial fi brillation and implanted continuous pacemakers volunteered for the study. Subject 1, the 75-yr-old subject, had a history of atrial fi brillation and fl utter with a history of multiple cardioversion attempts followed by ablation in 2009 without improvement. A permanent, dual-lead, rate-responsive pacemaker was placed in 2010. He had no history of syncope related to his dysrhythmias and had been approved by the Federal Aviation Administration (FAA) for a special issuance authorization for a third-class medical certifi cate for fl ight as a private pilot. He participated in regular single-pilot fl ying as recently as 2 yr prior to his participation in the centrifuge study. His medical history also includes hypertension and prostate cancer, for which he had undergone surgery under general anesthetic 11 mo prior to his participation with no reported complications. Electrocardiograms (EKGs) demonstrated pacer spikes with successful capture, with sinus rhythm at 70 bpm. His medications include hydrochlorothiazide (25 mg daily), simvastatin (40 mg daily), and sotalol (80 mg three times daily).
Subject 2 is 79-yr-old with a history of atrial fi brillation, with multiple episodes of syncope related to his atrial fi brillation and chemical cardioversion for his dysrhythmias. Th is subject underwent permanent dual-lead, rate-responsive pacemaker placement in 2004, without further incident of syncope or dysrhythmia-related symptoms. Th e original device was replaced in 2012 without issues. He has a further history of hypertension and his medications include amlodipine (5 mg daily), lisinopril (40 mg daily), and rivaroxaban (10 mg daily). EKGs demonstrated pacer spikes with successful capture, with sinus rhythm at 76 bpm. Th is subject is very physically active, with regular cardiovascular and weight-training exercise multiple times per week.
Both subjects underwent 7 centrifuge runs over 2 d as a part of a larger trial of 86 individuals conducted at the National AeroSpace Training and Research (NASTAR, Environmental Tectonics Corp., Southampton, PA) Center centrifuge.
1 Day 1 consisted of two +G z runs (peak 5 +3.5 G z , run 2) and two +G x runs (peak 5 +6.0 G x , run 4). Day 2 consisted of three runs approximating suborbital spaceflight profiles (combined +G x /+G z ). Data collected included blood pressures, EKGs, pulse oximetry, neurovestibular exams, and postrun questionnaires regarding motion sickness, disorientation, greyout, and other symptoms.
Despite both subjects ' signifi cant medical histories, neither had abnormal physiological responses. Both subjects demonstrated lower average heart rate response during peak accelerations of all profi les when compared to subjects in the larger trial, though this fi nding was not statistically signifi cant.
1 Th e hemodynamic responses of the two subjects compared to average responses of subjects in the larger trial are provided in Table I . Subject 1 demonstrated a single PVC during the launch phase of Run 6, the fi rst full-strength integrated spacefl ight profi le. Th ere were no other abnormal rhythms observed in this subject. He reported no subjective symptoms of palpitations, lightheadedness, or discomfort during any of the runs, and his neurovestibular exams demonstrated no alteration from baseline aft er any of the centrifuge exposures. Subject 2 demonstrated multiple single-episode PACs and PVCs during all dynamic phases of all seven centrifuge runs. He did not report any symptoms of palpitations, light-headedness, or discomfort during any run. This subject demonstrated mild increasing neurovestibular imbalance aft er later centrifuge runs, not signifi cantly diff erent from expected imbalance following repetitive centrifuge exposure. 1 Both subjects were evaluated by their personal physicians and cardiologists following the centrifuge trials, and both 
DISCUSSION
This report represents the first known published cases of pacemaker-dependent individuals undergoing exposure to increased acceleration forces as would be seen during the launch and landing phases of commercial spacefl ight. As increased dysrhythmias have been seen during acceleration exposure of individuals with normal cardiac rhythms, there is signifi cant concern regarding the ability of an individual with a predilection toward abnormal cardiac rhythms, such as the subjects discussed here, to tolerate the dysrhythmic eff ects of increased +G z exposure. 6 , 7 Despite concerns, the subjects described here experienced no apparent adverse eff ects from the centrifuge runs. One subject demonstrated rhythm stability while the other demonstrated multiple PACs and PVCs; neither was symptomatic, and the subject experiencing PVCs retained successful rhythm capture despite the abnormal beats.
Other concerns for pacemaker-dependent subjects undergoing +G z acceleration exposure include the possibility of lead displacement with loss of device function. Th e subjects here had no such diffi culties, and post-trial analysis of the devices demonstrated no damage or abnormalities due to centrifuge exposure. Previous studies have demonstrated that the heart can shift caudally within the thoracic cavity by an average of 1.5 cm during acceleration exposure of +3 G z ; concerns have been raised that such caudal shift ing could adversely strain pacemaker leads, potentially dislodging or damaging lead wires. 5 , 8 Most studies suggest that pacemaker lead position may change, particularly during the fi rst year aft er placement; however, delayed dislodgement of a pacemaker lead is rare. 3 It is unlikely that the relatively slow onset of acceleration forces, as seen in both centrifuge and anticipated commercial spacefl ight profi les, would be suffi cient to cause lead displacement, even with caudal heart displacement. Further, pacemaker leads are placed so as to provide enough slack that patients are able to perform activities of daily life without concern of lead displacement or fracture; similarly, heart displacement secondary to these relatively low +G z exposures is not likely to exceed normal heart displacement during daily routines or the tolerance provided by normal lead slack.
A case report was published in 1999 that discussed cardiac pacemaker failure in a pilot due to myocardial scarring and a fractured pacemaker lead unrelated to fl ight activities. 10 In that case, the most pressing concern was for sudden incapacitation and hemodynamic compromise in an airman fl ying a vehicle. As SFPs have a largely passive role during fl ight, sudden incapacitation due to pacemaker malfunction or failure does not carry the same risks for an SFP as it would for a pilot or crewmember. In addition, there are very low rates of lead failures leading to loss of pacing capability (most studies report rates of less than 1% aft er the initial month following surgery), thus the likelihood of an in-fl ight incapacitating event for a passenger can be considered to be very unlikely. 12 The symptoms of CID malfunction or failure should be reviewed with SFPs prior to launch so that they may rapidly recognize any problems and can alert fl ight crew for notifi cation of ground medical teams. 12 Ground crews should be fully equipped to respond to in-fl ight medical emergencies immediately upon landing, with available external pacing, defi brillation, and life support capabilities.
While the cases reviewed here have highlighted the potential for individuals with CIDs to tolerate the acceleration forces of commercial suborbital spacefl ight, further investigation is warranted to identify any additional limitations imposed by specifi c medical conditions and medications taken in conjunction with the use of CIDs. Th ese cases do not address the ongoing concerns of implanted defi brillation devices, as the risks associated, particularly the possibility of inappropriate shock secondary to acceleration-induced dysrhythmias, were considered too signifi cant to be evaluated in this setting. It may be that the use of an implanted automated defi brillator in a space vehicle poses risks that may simply prohibit the inclusion of persons requiring such devices from spacefl ight.
In addition, the cases presented here did not address the radiation environment of space, which may have deleterious effects on implanted medical devices. Previous work has addressed this issue for commercial spacefl ight and suggests that short-duration, suborbital fl ights pose little risk regarding radiation aff ecting device function, though the issue should be readdressed prior to longer-duration, orbital spaceflight. 12 Finally, the use of electrical devices within a space vehicle should be preceded by the evaluation of the device to ensure that the device itself does not interfere with the avionic equipment required for vehicle operations, nor that the avionic equipment in any way interferes with the proper function of the medical device. 4 , 11 , 12 Th e expansion of the number of commercial SFPs will necessitate a paradigm shift within aerospace medicine. Aerospace medicine specialists must become more comfortable with individuals who may have signifi cant medical conditions participating in spacefl ight. While individual cases still warrant evaluation and risk assessment, the cases discussed here show that even individuals with signifi cant cardiovascular disease history and implanted medical devices may be able to tolerate the acceleration exposures of commercial spacefl ight.
